These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38684226)

  • 1. Concurrent Optimizations of Efficacy and Blood-Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson's Disease Therapeutics.
    Kim K; Jang A; Shin H; Ye I; Lee JE; Kim T; Park H; Hong S
    J Med Chem; 2024 May; 67(9):7647-7662. PubMed ID: 38684226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson's Disease.
    Sebastián-Pérez V; Martínez MJ; Gil C; Campillo NE; Martínez A; Ponzoni I
    J Integr Bioinform; 2019 Feb; 16(1):. PubMed ID: 30763264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.
    Christensen KV; Smith GP; Williamson DS
    Prog Med Chem; 2017; 56():37-80. PubMed ID: 28314412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease.
    Koshibu K; van Asperen J; Gerets H; Garcia-Ladona J; Lorthioir O; Courade JP
    Pharmacology; 2015; 96(5-6):240-7. PubMed ID: 26382237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.
    Patel A; Patel S; Mehta M; Patel Y; Langaliya D; Bhalodiya S; Bambharoliya T
    Med Chem; 2022; 18(7):757-771. PubMed ID: 35168510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
    Galatsis P
    Expert Opin Ther Pat; 2017 Jun; 27(6):667-676. PubMed ID: 28117607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Preliminary Evaluation of [
    Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S
    ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
    Ray S; Liu M
    Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
    Greshock TJ; Sanders JM; Drolet RE; Rajapakse HA; Chang RK; Kim B; Rada VL; Tiscia HE; Su H; Lai MT; Sur SM; Sanchez RI; Bilodeau MT; Renger JJ; Kern JT; McCauley JA
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2631-5. PubMed ID: 27106707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy.
    Ding X; Stasi LP; Dai X; Long K; Peng C; Zhao B; Wang H; Sun C; Hu H; Wan Z; Jandu KS; Philps OJ; Chen Y; Wang L; Liu Q; Edge C; Li Y; Dong K; Guan X; Tattersall FD; Reith AD; Ren F
    Bioorg Med Chem Lett; 2019 Jan; 29(2):212-215. PubMed ID: 30522952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
    Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
    ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-Molecule Inhibitors of LRRK2.
    Hatcher JM; Choi HG; Alessi DR; Gray NS
    Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.
    Baidya AT; Deshwal S; Das B; Mathew AT; Devi B; Sandhir R; Kumar R
    Bioorg Chem; 2024 Feb; 143():106972. PubMed ID: 37995640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
    Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ
    Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
    Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
    J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.
    Ding X; Dai X; Long K; Peng C; Andreotti D; Bamborough P; Eatherton AJ; Edge C; Jandu KS; Nichols PL; Philps OJ; Stasi LP; Wan Z; Xiang JN; Dong K; Dossang P; Ho MH; Li Y; Mensah L; Guan X; Reith AD; Ren F
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4034-4038. PubMed ID: 28774425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2).
    Konstantinidou M; Oun A; Pathak P; Zhang B; Wang Z; Ter Brake F; Dolga AM; Kortholt A; Dömling A
    ChemMedChem; 2021 Mar; 16(6):959-965. PubMed ID: 33278061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
    Salado IG; Zaldivar-Diez J; Sebastián-Pérez V; Li L; Geiger L; González S; Campillo NE; Gil C; Morales AV; Perez DI; Martinez A
    Eur J Med Chem; 2017 Sep; 138():328-342. PubMed ID: 28688273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.